GHK-Cu is the copper peptide behind a large part of the peptide skincare category. The laboratory and gene-expression literature is substantial; the controlled clinical literature in humans is much thinner than the marketing suggests.
GHK-Cu is the most commercially successful peptide in skincare, and one of the least carefully described. It has a real research history stretching back to the 1970s, a plausible biochemical story, and a clinical evidence base that does not match the confidence of its marketing.
GHK is a tripeptide — glycyl-L-histidyl-L-lysine — that occurs naturally in human plasma and whose plasma level declines with age. GHK-Cu is that tripeptide in complex with copper(II). The copper is not incidental: much of the proposed activity is attributed to the peptide acting as a copper carrier, delivering the ion in a form cells can use.
The published work, much of it reviewed by Loren Pickart — the researcher who originally isolated GHK — covers three broad areas:
Gene expression. The 2018 review in the International Journal of Molecular Sciences summarises analyses in which GHK-Cu was associated with modulation of a large number of human genes in cell systems, including genes involved in extracellular-matrix remodelling and antioxidant response.
Matrix and wound repair. Laboratory and animal work reports effects on collagen and glycosaminoglycan synthesis by fibroblasts, and on aspects of wound remodelling.
Cosmetic skin outcomes. Smaller studies in humans report changes in skin appearance measures such as firmness, roughness and fine-line assessment after topical use.
A long list of modulated genes in a cell system is a description of biological activity, not of a clinical benefit.
Three limitations should be read alongside every claim:
Author concentration. A large proportion of the reviews and mechanistic framing come from the same small group of authors, who also have commercial involvement in copper-peptide products. That does not make the work wrong; it means independent replication matters more than usual.
Study size and design. Human data are dominated by small, often unblinded cosmetic studies with subjective or instrument-derived appearance endpoints, rather than large randomised trials.
Formulation dependence. Topical results depend on concentration, vehicle, pH and copper stability. A result obtained with one formulation does not transfer to any product containing the ingredient name.
In cosmetics, GHK-Cu is used as a topical ingredient, and cosmetic products are regulated on safety and labelling rather than on demonstrated efficacy. The moment a product claims to treat a disease or alter the structure of the body in a therapeutic way, it enters drug regulation — a line the FDA draws explicitly, and which much peptide-skincare copy sits close to. Injectable GHK-Cu is not an approved medicine, and this publication gives no injection, reconstitution or dosing guidance for it.
GHK-Cu is one of the better-supported ingredients in the peptide skincare category, judged against a low bar. There is coherent biochemistry, a copper-delivery rationale and repeated in-vitro signal. What is missing is the large, blinded, independently run clinical evidence that would justify statements about reversing skin ageing. Claims about longevity, organ regeneration or systemic anti-ageing effects in humans go well past what has been shown.
The interesting part of GHK-Cu is the mechanism: an endogenous tripeptide that declines with age and carries copper into cells. The overstated part is everything downstream of that. Treat the gene-expression work as a hypothesis generator, the cosmetic studies as small and formulation-specific, and any systemic anti-ageing claim as unsupported.
The two 2018 reviews and their PubMed Central full text are the primary material, together with the FDA's cosmetics regulation pages for the claims boundary.